{"DataElement":{"publicId":"13752210","version":"1","preferredName":"Modified Toxicity Criteria Skin Rash Condition Grade","preferredDefinition":"A description of the modified toxicity criteria for skin rash grade.","longName":"13752119v1.00:13752161v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"13752119","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Skin Rash Condition","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.:Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful._A state of being, such as a state of health.","longName":"13751560v1.00:13752118v1.00","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"13751560","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","longName":"C199478","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED37C0-8F10-1878-E053-731AD00AD0C4","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13752118","version":"1","preferredName":"Skin Rash Condition","preferredDefinition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful._A state of being, such as a state of health.","longName":"C39594:C25457","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Rash","conceptCode":"C39594","definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Condition","conceptCode":"C25457","definition":"A state of being, such as a state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDFC82-C2E2-34C1-E053-731AD00ADDB8","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDFC82-C2E3-34C1-E053-731AD00ADDB8","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13752161","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Skin Rash Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful._A position on a scale of intensity or amount or quality.","longName":"13752161v1.00","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"120","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":null,"ValueMeaning":{"publicId":"13707077","version":"1","preferredName":"None","longName":"13707077v1.00","preferredDefinition":"None (grade 0)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC997DFD-C173-2136-E053-731AD00AF445","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEED048-04DE-5E83-E053-731AD00A3F25","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Macular or papular eruption or erythema that is asymptomatic","valueDescription":null,"ValueMeaning":{"publicId":"13752181","version":"1","preferredName":"Macular or papular eruption or erythema that is asymptomatic","longName":"13752181v1.00","preferredDefinition":"Macular or papular eruption or erythema that is asymptomatic (discrete areas of raised or flat, discolored and/or reddened skin patches, with no other symptoms) (grade 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEED048-04DA-5E83-E053-731AD00A3F25","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEED048-04DF-5E83-E053-731AD00A3F25","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Macular or papular eruption or erythema with pruritus or other associated symptoms","valueDescription":null,"ValueMeaning":{"publicId":"13752182","version":"1","preferredName":"Macular or papular eruption or erythema with pruritus or other associated symptoms","longName":"13752182v1.00","preferredDefinition":"Macular or papular eruption or erythema with pruritus or other associated symptoms (discrete areas of raised or flat, discolored and/or reddened skin patches, in conjunction with symptoms such as itching and pain) (grade 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEED048-04DB-5E83-E053-731AD00A3F25","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEED048-04E0-5E83-E053-731AD00A3F25","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Severe, generalized erythroderma or macular, papular, or vesicular eruption","valueDescription":null,"ValueMeaning":{"publicId":"13752183","version":"1","preferredName":"Severe, generalized erythroderma or macular, papular, or vesicular eruption","longName":"13752183v1.00","preferredDefinition":"Severe, generalized erythroderma or macular, papular, or vesicular eruption (discrete areas of raised or flat, discolored and/or reddened skin patches with the possible addition of fluid-filled blisters; also, the condition is not widely spaced, but instead covers the majority of the body) (grade 3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEED048-04DC-5E83-E053-731AD00A3F25","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEED048-04E1-5E83-E053-731AD00A3F25","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Generalized exfoliative dermatitis or ulcerating dermatitis","valueDescription":null,"ValueMeaning":{"publicId":"13752184","version":"1","preferredName":"Generalized exfoliative dermatitis or ulcerating dermatitis","longName":"13752184v1.00","preferredDefinition":"Generalized exfoliative dermatitis or ulcerating dermatitis (skin inflammation leading to peeling and/or ulceration) (grade 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEED048-04DD-5E83-E053-731AD00A3F25","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEED048-04E2-5E83-E053-731AD00A3F25","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13752160","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Skin Rash Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful._A position on a scale of intensity or amount or quality.","longName":"13752160v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Skin Rash","conceptCode":"C39594","definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE37F1-DE9B-4024-E053-731AD00A9682","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE37F1-DE9C-4024-E053-731AD00A9682","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak2023.5.30 Created per ticket request CADSR0002455. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the modified toxicity criteria for skin rash grade?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Rashes on skin","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEFC526-28D5-0A28-E053-731AD00A7EA5","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}